A456070 Stock Overview
Develops cell/gene-based biopharmaceutical products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ENCell Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩24,500.00 |
| 52 Week High | ₩45,800.00 |
| 52 Week Low | ₩16,740.00 |
| Beta | 0 |
| 11 Month Change | -10.26% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 42.44% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| A456070 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 10.9% | 3.9% | -0.5% |
| 1Y | n/a | 56.0% | 7.3% |
Return vs Industry: Insufficient data to determine how A456070 performed against the KR Life Sciences industry.
Return vs Market: Insufficient data to determine how A456070 performed against the KR Market.
Price Volatility
| A456070 volatility | |
|---|---|
| A456070 Average Weekly Movement | 25.4% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A456070's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A456070's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | n/a | encellinc.com |
ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.
ENCell Co., Ltd. Fundamentals Summary
| A456070 fundamental statistics | |
|---|---|
| Market cap | ₩260.91b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A456070 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A456070 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A456070 perform over the long term?
See historical performance and comparison